H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Anavex (AVXL) to $42 from $40 and keeps a Buy rating on the shares after the company announced the acceptance of the blarcamesine Marketing Authorization Application for the treatment of Alzheimer’s disease for review by the European Medicines Agency. The “timely acceptance” of the MAA for blarcamesine reflects at least in part the EMA’s recognition of the severe unmet medical need in Alzheimer’s, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial Stability
- Nordstrom family to take chain private: Morning Buzz
- Anavex reports Q4 EPS (14c) vs. (12c) last year
- Anavex sees cash runway of four years
- Anavex receives EMA filing acceptance for treatment of Alzheimer’s disease